Victoria Langowska , 2025-05-14 17:23:00
In this video, Ursula A. Matulonis, MD, discusses results from the phase 3 MIRASOL trial of mirvetuximab soravtansine-gynx for patients with folate receptor alpha-positive, platinum-resistant ovarian cancer.
Results of the trial, which evaluated the efficacy and safety of mirvetuximab soravtansine-gynx (Elahere, AbbVie), were presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.
“The median overall survival for patients receiving mirvetuximab was 16.85 months vs. 13.34 months for investigator’s choice chemotherapy, with a hazard ratio of 0.68,” Matulonis, chief of the division of gynecologic oncology at Dana-Farber Cancer Institute and professor at Harvard Medical School, said. “The final median PFS for mirvetuximab was 5.59 months vs. 3.98 months for investigator’s choice chemotherapy.”
Sources/Disclosures
Collapse
Source:
Healio interviews
Disclosures:
Matulonis reports consulting fees from Merck; data safety monitoring board participation for Mural Oncology and Symphogen; and scientific advisory board participation for Abbvie, Allarity, Daiichi Sankyo, Eisai, GSK, Immunogen, NextCure, Novartis, Profound Bio, Tango Therapeutics and the Ovarian Cancer Research Alliance.
